The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.
Journal
Targeted oncology
ISSN: 1776-260X
Titre abrégé: Target Oncol
Pays: France
ID NLM: 101270595
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
accepted:
23
02
2022
pubmed:
16
3
2022
medline:
13
4
2022
entrez:
15
3
2022
Statut:
ppublish
Résumé
Gastrointestinal stromal tumours (GISTs) are the most common gastrointestinal tract mesenchymal tumours. Tyrosine kinase inhibitors (TKIs) have transformed the management of advanced GIST. Imatinib was the first TKI to gain approval as management for patients with advanced GIST, establishing a new standard of care. Since then, as a result of several trials including the GRID and INVICTUS studies, we now have five lines of approved targeted therapy, including imatinib, sunitinib, regorafenib, ripretinib and avapritinib for the treatment of unresectable, advanced GISTs. In this review, the Australasian Gastrointestinal Trials Group (AGITG) provide an overview of the key trials that have changed clinical practice, discuss the molecular drivers of GISTs, the importance of molecular testing and directing therapy according to molecular targets, as well as future strategies in the management of advanced GISTs.
Identifiants
pubmed: 35290591
doi: 10.1007/s11523-022-00869-y
pii: 10.1007/s11523-022-00869-y
pmc: PMC8995292
doi:
Substances chimiques
Antineoplastic Agents
0
Protein Kinase Inhibitors
0
Imatinib Mesylate
8A1O1M485B
Sunitinib
V99T50803M
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
95-110Informations de copyright
© 2022. Crown.
Références
Kindblom LG, Remotti HE, Aldenborg F, Meis-Kindblom JM. Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152(5):1259–69.
pubmed: 9588894
pmcid: 1858579
Parab TM, DeRogatis MJ, Boaz AM, Grasso SA, Issack PS, Duarte DA, et al. Gastrointestinal stromal tumors: a comprehensive review. J Gastrointest Oncol. 2019;10(1):144–54. https://doi.org/10.21037/jgo.2018.08.20 .
doi: 10.21037/jgo.2018.08.20
pubmed: 30788170
pmcid: 6351301
Søreide K, Sandvik OM, Søreide JA, Giljaca V, Jureckova A, Bulusu VR. Global epidemiology of gastrointestinal stromal tumours (GIST): A systematic review of population-based cohort studies. Cancer Epidemiol. 2016;40:39–46. https://doi.org/10.1016/j.canep.2015.10.031 .
doi: 10.1016/j.canep.2015.10.031
pubmed: 26618334
Mei L, Smith SC, Faber AC, Trent J, Grossman SR, Stratakis CA, et al. Gastrointestinal stromal tumors: the GIST of precision medicine. Trends Cancer. 2018;4(1):74–91. https://doi.org/10.1016/j.trecan.2017.11.006 .
doi: 10.1016/j.trecan.2017.11.006
pubmed: 29413424
Boikos SA, Pappo AS, Killian JK, LaQuaglia MP, Weldon CB, George S, et al. Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic. JAMA Oncol. 2016;2(7):922–8. https://doi.org/10.1001/jamaoncol.2016.0256 .
doi: 10.1001/jamaoncol.2016.0256
pubmed: 27011036
pmcid: 5472100
Benesch M, Wardelmann E, Ferrari A, Brennan B, Verschuur A. Gastrointestinal stromal tumors (GIST) in children and adolescents: a comprehensive review of the current literature. Pediatr Blood Cancer. 2009;53(7):1171–9. https://doi.org/10.1002/pbc.22123 .
doi: 10.1002/pbc.22123
pubmed: 19499582
Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer. 2011;11(12):865–78. https://doi.org/10.1038/nrc3143 .
doi: 10.1038/nrc3143
pubmed: 22089421
Lasota J, Miettinen M. KIT and PDGFRA mutations in gastrointestinal stromal tumors (GISTs). Semin Diagn Pathol. 2006;23(2):91–102. https://doi.org/10.1053/j.semdp.2006.08.006 .
doi: 10.1053/j.semdp.2006.08.006
pubmed: 17193822
Kelly CM, Gutierrez Sainz L, Chi P. The management of metastatic GIST: current standard and investigational therapeutics. J Hematol Oncol. 2021;14(1):2. https://doi.org/10.1186/s13045-020-01026-6 .
doi: 10.1186/s13045-020-01026-6
pubmed: 33402214
pmcid: 7786896
Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998;279(5350):577–80. https://doi.org/10.1126/science.279.5350.577 .
doi: 10.1126/science.279.5350.577
pubmed: 9438854
Bannon AE, Klug LR, Corless CL, Heinrich MC. Using molecular diagnostic testing to personalize the treatment of patients with gastrointestinal stromal tumors. Expert Rev Mol Diagn. 2017;17(5):445–57. https://doi.org/10.1080/14737159.2017.1308826 .
doi: 10.1080/14737159.2017.1308826
pubmed: 28317407
Martín J, Poveda A, Llombart-Bosch A, Ramos R, López-Guerrero JA, García del Muro J, et al. Deletions affecting codons 557–558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol. 2005;23(25):6190–8. https://doi.org/10.1200/JCO.2005.19.554 .
doi: 10.1200/JCO.2005.19.554
pubmed: 16135486
Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol. 2000;156(3):791–5. https://doi.org/10.1016/S0002-9440(10)64946-2 .
doi: 10.1016/S0002-9440(10)64946-2
pubmed: 10702394
pmcid: 1876850
Oppelt PJ, Hirbe AC, Van Tine BA. Gastrointestinal stromal tumors (GISTs): point mutations matter in management, a review. J Gastrointest Oncol. 2017;8(3):466–73. https://doi.org/10.21037/jgo.2016.09.15 .
doi: 10.21037/jgo.2016.09.15
pubmed: 28736634
pmcid: 5506287
Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53(3):245–66. https://doi.org/10.1111/j.1365-2559.2008.02977.x .
doi: 10.1111/j.1365-2559.2008.02977.x
pubmed: 18312355
Lasota J, Corless CL, Heinrich MC, Debiec-Rychter M, Sciot R, Wardelmann E, et al. Clinicopathologic profile of gastrointestinal stromal tumors (GISTs) with primary KIT exon 13 or exon 17 mutations: a multicenter study on 54 cases. Mod Pathol. 2008;21(4):476–84. https://doi.org/10.1038/modpathol.2008.2 .
doi: 10.1038/modpathol.2008.2
pubmed: 18246046
Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell P, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23(23):5357–64. https://doi.org/10.1200/JCO.2005.14.068 .
doi: 10.1200/JCO.2005.14.068
pubmed: 15928335
Indio V, Astolfi A, Tarantino G, Urbini M, Patterson J, Nannini M, et al. Integrated molecular characterization of gastrointestinal stromal tumors (GIST) harboring the rare D842V mutation in PDGFRA gene. Int J Mol Sci. 2018;19(3):732. https://doi.org/10.3390/ijms19030732 .
doi: 10.3390/ijms19030732
pmcid: 5877593
Lasota J, Stachura J, Miettinen M. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Investig. 2006;86(1):94–100. https://doi.org/10.1038/labinvest.3700360 .
doi: 10.1038/labinvest.3700360
pubmed: 16258521
Chetty R, Serra S. Molecular and morphological correlation in gastrointestinal stromal tumours (GISTs): an update and primer. J Clin Pathol. 2016;69(9):754–60. https://doi.org/10.1136/jclinpath-2016-203807 .
doi: 10.1136/jclinpath-2016-203807
pubmed: 27317811
Carney JA, Sheps SG, Go VLW, Gordon H. The triad of gastric leiomyosarcoma, functioning extra-adrenal paraganglioma and pulmonary chondroma. N Engl J Med. 1977;296(26):1517–8. https://doi.org/10.1056/NEJM197706302962609 .
doi: 10.1056/NEJM197706302962609
pubmed: 865533
Carney JA. Carney triad. In: Stratakis CA, editor. Endocrine tumor syndromes and their genetics, Frontiers of hormone research, vol. 41. Basel: Karger; 2013. p. 92–110. https://doi.org/10.1159/000345672 .
doi: 10.1159/000345672
Carney JA, Stratakis CA. Familial paraganglioma and gastric stromal sarcoma: a new syndrome distinct from the Carney triad. Am J Med Genet. 2002;108(2):132–9. https://doi.org/10.1002/ajmg.10235 .
doi: 10.1002/ajmg.10235
pubmed: 11857563
Zhang L, Smyrk TC, Young WFJ, Stratakis CA, Carney JA. Gastric stromal tumors in Carney triad are different clinically, pathologically, and behaviorally from sporadic gastric gastrointestinal stromal tumors: findings in 104 cases. Am J Surg Pathol. 2010;34(1):53–64. https://doi.org/10.1097/PAS.0b013e3181c20f4f .
doi: 10.1097/PAS.0b013e3181c20f4f
pubmed: 19935059
pmcid: 3652406
Pasini B, McWhinney SR, Bei T, Matyakhina L, Stergiopoulos S, Muchow M, et al. Clinical and molecular genetics of patients with the Carney-Stratakis syndrome and germline mutations of the genes coding for the succinate dehydrogenase subunits SDHB, SDHC, and SDHD. Eur J Hum Genet. 2008;16(1):79–88. https://doi.org/10.1038/sj.ejhg.5201904 .
doi: 10.1038/sj.ejhg.5201904
pubmed: 17667967
Gaal J, Stratakis CA, Carney JA, Ball ER, Korpershoek E, Lodish MB, et al. SDHB immunohistochemistry: a useful tool in the diagnosis of Carney-Stratakis and Carney triad gastrointestinal stromal tumors. Mod Pathol. 2011;24(1):147–51. https://doi.org/10.1038/modpathol.2010.185 .
doi: 10.1038/modpathol.2010.185
pubmed: 20890271
Favier J, Amar L, Gimenez-Roqueplo AP. Paraganglioma and phaeochromocytoma: from genetics to personalized medicine. Nat Rev Endocrinol. 2015;11(2):101–11. https://doi.org/10.1038/nrendo.2014.188 .
doi: 10.1038/nrendo.2014.188
pubmed: 25385035
Miettinen M, Fetsch JF, Sobin LH, Lasota J. Gastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 cases. Am J Surg Pathol. 2006;30(1):90–6. https://doi.org/10.1097/01.pas.0000176433.81079.bd .
doi: 10.1097/01.pas.0000176433.81079.bd
pubmed: 16330947
Hostein I, Faur N, Primois C, Boury F, Denard J, Emile JF, et al. BRAF mutation status in gastrointestinal stromal tumors. Am J Clin Pathol. 2010;133(1):141–8. https://doi.org/10.1309/AJCPPCKGA2QGBJ1R .
doi: 10.1309/AJCPPCKGA2QGBJ1R
pubmed: 20023270
Agaram NP, Wong GC, Guo T, Maki RG, Singer S, DeMatteo RP, et al. Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors. Genes Chromosomes Cancer. 2008;47(10):853–9.
doi: 10.1002/gcc.20589
Casali PG, Blay JY, Abecassis N, Bajpai J, Bauer S, Biagini R, et al. Gastrointestinal stromal tumours: ESMO-EURACAN-GENTURIS clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(1):20–33. https://doi.org/10.1016/j.annonc.2021.09.005 .
doi: 10.1016/j.annonc.2021.09.005
pubmed: 34560242
NCCN clinical practice guidelines in oncology- gastrointestinal stromal tumors (GISTs) version 1.2022–21 January 2022. https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf . Accessed 20 Jan 2022.
Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G. Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002;33(5):466–77. https://doi.org/10.1053/hupa.2002.124122 .
doi: 10.1053/hupa.2002.124122
pubmed: 12094371
O’Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994–1004. https://doi.org/10.1056/NEJMoa022457 .
doi: 10.1056/NEJMoa022457
pubmed: 12637609
Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahartiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med. 2001;344(14):1052–6. https://doi.org/10.1056/NEJM200104053441404 .
doi: 10.1056/NEJM200104053441404
pubmed: 11287975
van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet. 2001;358(9291):1421–3. https://doi.org/10.1016/s0140-6736(01)06535-7 .
doi: 10.1016/s0140-6736(01)06535-7
pubmed: 11705489
Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347(7):472–80. https://doi.org/10.1056/NEJMoa020461 .
doi: 10.1056/NEJMoa020461
pubmed: 12181401
Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res. 2002;8(10):3034–8.
pubmed: 12374669
Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004;364(9440):1127–34. https://doi.org/10.1016/S0140-6736(04)17098-0 .
doi: 10.1016/S0140-6736(04)17098-0
pubmed: 15451219
Casali PG, Zalcberg J, Le Cesne A, Reichardt P, Blay JY, Lindner LH, et al. Ten-year progression-free and overall survival in patients with unresectable or metastatic gi stromal tumors: long-term analysis of the european organisation for research and treatment of cancer, Italian Sarcoma Group, and Australasian Gastrointestinal Tr. J Clin Oncol. 2017;35(15):1713–20. https://doi.org/10.1200/JCO.2016.71.0228 .
doi: 10.1200/JCO.2016.71.0228
pubmed: 28362562
Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26(4):626–32. https://doi.org/10.1200/JCO.2007.13.4452 .
doi: 10.1200/JCO.2007.13.4452
pubmed: 18235122
Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CDM, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26(33):5360–7. https://doi.org/10.1200/JCO.2008.17.4284 .
doi: 10.1200/JCO.2008.17.4284
pubmed: 18955451
pmcid: 2651078
Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol. 2006;24(29):4764–74. https://doi.org/10.1200/JCO.2006.06.2265 .
doi: 10.1200/JCO.2006.06.2265
pubmed: 16954519
Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients. J Clin Oncol. 2010;28(7):1247-1253. doi: https://doi.org/10.1200/JCO.2009.24.2099
Casali PG, Abecassis N, Bauer S, Biagini R, Bielack S, Bonvalot S, et al. Gastrointestinal stromal tumours: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29:iv68–78. https://doi.org/10.1093/annonc/mdy095 .
doi: 10.1093/annonc/mdy095
pubmed: 29846513
Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY, et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer. 2005;41(12):1751–7. https://doi.org/10.1016/j.ejca.2005.04.034 .
doi: 10.1016/j.ejca.2005.04.034
pubmed: 16098458
Le Cesne A, Ray-Coquard I, Bui BN, Adenis A, Rios M, Bertucci F, et al. Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial. Lancet Oncol. 2010;11(10):942–9. https://doi.org/10.1016/S1470-2045(10)70222-9 .
doi: 10.1016/S1470-2045(10)70222-9
pubmed: 20864406
Heinrich MC, Corless CL, Demetri GD, Blanke CD, Von Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21(23):4342–9. https://doi.org/10.1200/JCO.2003.04.190 .
doi: 10.1200/JCO.2003.04.190
pubmed: 14645423
Heinrich MC, Jones RL, von Mehren M, Schöffski P, Serrano C, Kang YK, et al. Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial. Lancet Oncol. 2020;21(7):935–46. https://doi.org/10.1016/S1470-2045(20)30269-2 .
doi: 10.1016/S1470-2045(20)30269-2
pubmed: 32615108
Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M, et al. Use of c-kit/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004;40(5):689–95. https://doi.org/10.1016/j.ejca.2003.11.025 .
doi: 10.1016/j.ejca.2003.11.025
pubmed: 15010069
Cassier PA, Fumagalli E, Rutkowski P, Schöffski P, Van Glabbeke M, Debiec-Rychter M, et al. Outcome of patients with platelet-derived growth factor receptor alpha-mutated gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Clin Cancer Res. 2012;18(16):4458–64. https://doi.org/10.1158/1078-0432.CCR-11-3025 .
doi: 10.1158/1078-0432.CCR-11-3025
pubmed: 22718859
Falchook GS, Trent JC, Heinrich MC, Beadling C, Patterson J, Bastida CC, et al. BRAF mutant gastrointestinal stromal tumor: first report of regression with BRAF inhibitor dabrafenib (GSK2118436) and whole exomic sequencing for analysis of acquired resistance. Oncotarget. 2013;4(2):310–5. https://doi.org/10.18632/oncotarget.864 .
doi: 10.18632/oncotarget.864
pubmed: 23470635
pmcid: 3712576
US FDA. FDA approves avapritinib for gastrointestinal stromal tumor with a rare mutation. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-avapritinib-gastrointestinal-stromal-tumor-rare-mutation . Accessed 17 Aug 2021.
Chen LL, Trent JC, Wu EF, Fuller GN, Ramdas L, Zhang W, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res. 2004;64(17):5913–9. https://doi.org/10.1158/0008-5472.CAN-04-0085 .
doi: 10.1158/0008-5472.CAN-04-0085
pubmed: 15342366
Dimitrakopoulou-Strauss A, Ronellenfitsch U, Cheng C, Pan L, Sachpekidis C, Hohenberger P, et al. Imaging therapy response of gastrointestinal stromal tumors (GIST) with FDG PET, CT and MRI: a systematic review. Clin Transl Imaging. 2017;5(3):183–97. https://doi.org/10.1007/s40336-017-0229-8 .
doi: 10.1007/s40336-017-0229-8
pubmed: 29104864
pmcid: 5658474
Choi H, Charnsangavej C, de Castro FS, Tamm EP, Benjamin RS, Johnson MM, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. AJR Am J Roentgenol. 2004;183(6):1619–28. https://doi.org/10.2214/ajr.183.6.01831619 .
doi: 10.2214/ajr.183.6.01831619
pubmed: 15547201
Yip D, Zalcberg JR, Blay JY, Eriksson M, Espinoza D, Price TJ, et al. ALT-GIST: Randomized phase II trial of imatinib alternating with regorafenib versus imatinib alone for the first-line treatment of metastatic gastrointestinal stromal tumor (GIST). J Clin Oncol. 2019;37(15 Suppl):11023. https://doi.org/10.1200/JCO.2019.37.15_suppl.11023 .
doi: 10.1200/JCO.2019.37.15_suppl.11023
O’Farrell AM, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KWH, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003;101(9):3597–605. https://doi.org/10.1182/blood-2002-07-2307 .
doi: 10.1182/blood-2002-07-2307
pubmed: 12531805
Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther. 2003;2(5):471–8.
pubmed: 12748309
Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res. 2003;9(1):327–37.
pubmed: 12538485
Osusky KL, Hallahan DE, Fu A, Ye F, Shyr Y, Geng L. The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels. Angiogenesis. 2004;7(3):225–33. https://doi.org/10.1007/s10456-004-3149-y .
doi: 10.1007/s10456-004-3149-y
pubmed: 15609077
Heinrich MC, Maki RG, Corless CL, Antonescu CR, Fletcher JA, Fletcher CD, et al. Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. J Clin Oncol. 2006;24(18 Suppl):9502. https://doi.org/10.1200/jco.2006.24.18_suppl.9502 .
doi: 10.1200/jco.2006.24.18_suppl.9502
Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368(9544):1329–38. https://doi.org/10.1016/S0140-6736(06)69446-4 .
doi: 10.1016/S0140-6736(06)69446-4
pubmed: 17046465
Goodman VL, Rock EP, Dagher R, Ramchandani RP, Abraham S, Gobburu JVS, et al. Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007;13(5):1367–73. https://doi.org/10.1158/1078-0432.CCR-06-2328 .
doi: 10.1158/1078-0432.CCR-06-2328
pubmed: 17332278
George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009;45(11):1959–68. https://doi.org/10.1016/j.ejca.2009.02.011 .
doi: 10.1016/j.ejca.2009.02.011
pubmed: 19282169
Napolitano A, Vincenzi B. Secondary KIT mutations: the GIST of drug resistance and sensitivity. Br J Cancer. 2019;120(6):577–8. https://doi.org/10.1038/s41416-019-0388-7 .
doi: 10.1038/s41416-019-0388-7
pubmed: 30792534
pmcid: 6461933
Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26(33):5352–9. https://doi.org/10.1200/JCO.2007.15.7461 .
doi: 10.1200/JCO.2007.15.7461
pubmed: 18955458
pmcid: 2651076
Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schütz G, et al. Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–55. https://doi.org/10.1002/ijc.25864 .
doi: 10.1002/ijc.25864
pubmed: 21170960
George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012;30(19):2401–7. https://doi.org/10.1200/JCO.2011.39.9394 .
doi: 10.1200/JCO.2011.39.9394
pubmed: 22614970
pmcid: 3675695
Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302. https://doi.org/10.1016/S0140-6736(12)61857-1 .
doi: 10.1016/S0140-6736(12)61857-1
pubmed: 23177515
Ingram I. FDA Approves Regorafenib (Stivarga) for GIST. https://www.cancernetwork.com/view/fda-approves-regorafenib-stivarga-gist . Accessed 16 Aug 2021.
Kang YK, George S, Jones RL, Rutkowski P, Shen L, Mir O, et al. Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: a randomized, open-label phase III study. J Clin Oncol. 2021;39(28):3128–39. https://doi.org/10.1200/JCO.21.00217 .
doi: 10.1200/JCO.21.00217
pubmed: 34343033
FDA approves ripretinib for advanced gastrointestinal stromal tumor | FDA. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ripretinib-advanced-gastrointestinal-stromal-tumor . Accessed 14 Aug 2021.
QINLOCK® (ripretinib) clinical overview. Spec Ther. 2021.
Janku F, Abdul Razak AR, Chi P, Heinrich MC, von Mehren M, Jones RL, et al. Switch control inhibition of KIT and PDGFRA in patients with advanced gastrointestinal stromal tumor: a phase I study of ripretinib. J Clin Oncol. 2020;38(28):3294–303. https://doi.org/10.1200/JCO.20.00522 .
doi: 10.1200/JCO.20.00522
pubmed: 32804590
pmcid: 7526717
Blay JY, Serrano C, Heinrich MC, Zalcberg J, Bauer S, Gelderblom H, et al. Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21(7):923–34. https://doi.org/10.1016/S1470-2045(20)30168-6 .
doi: 10.1016/S1470-2045(20)30168-6
pubmed: 32511981
pmcid: 8383051
Zalcberg JR, Heinrich MC, George S, Bauer S, Schöffski P, Serrano C, et al. Clinical benefit of ripretinib dose escalation after disease progression in advanced gastrointestinal stromal tumor: an analysis of the INVICTUS study. Oncologist. 2021;26(11):e2053–60. https://doi.org/10.1002/onco.13917 .
doi: 10.1002/onco.13917
pubmed: 34313371
pmcid: 8571742
A Study of DCC-2618 vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03673501 . Accessed 21 Aug 2021.
Deciphera Pharmaceuticals announces top-line results from the INTRIGUE phase 3 clinical study. 2021. https://investors.deciphera.com/news-releases . Accessed 18 Jan 2022.
Schöffski P, Reichardt P, Blay JY, Dumez H, Morgan JA, Ray-Coquard I, et al. A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol. 2010;21(10):1990–8. https://doi.org/10.1093/annonc/mdq076 .
doi: 10.1093/annonc/mdq076
pubmed: 20507881
Gelderblom H, Jones RL, George S, Valverde Morales C, Benson C, Blay JY, et al. Imatinib in combination with phosphoinositol kinase inhibitor buparlisib in patients with gastrointestinal stromal tumour who failed prior therapy with imatinib and sunitinib: a Phase 1b, multicentre study. Br J Cancer. 2020;122(8):1158–65. https://doi.org/10.1038/s41416-020-0769-y .
doi: 10.1038/s41416-020-0769-y
pubmed: 32147671
pmcid: 7156686
Floris G, Wozniak A, Sciot R, Li H, Friedman L, Van Looy T, et al. A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal. Clin Cancer Res. 2013;19(3):620–30. https://doi.org/10.1158/1078-0432.CCR-12-2853 .
doi: 10.1158/1078-0432.CCR-12-2853
pubmed: 23231951
Van Looy T, Wozniak A, Floris G, Sciot R, Li H, Wellens J, et al. Phosphoinositide 3-kinase inhibitors combined with imatinib in patient-derived xenograft models of gastrointestinal stromal tumors: rationale and efficacy. Clin Cancer Res. 2014;20(23):6071–82. https://doi.org/10.1158/1078-0432.CCR-14-1823 .
doi: 10.1158/1078-0432.CCR-14-1823
pubmed: 25316817
Zook P, Pathak HB, Belinsky MG, Gersz L, Devarajan K, Zhou Y, et al. Combination of imatinib mesylate and AKT inhibitor provides synergistic effects in preclinical study of gastrointestinal stromal Tumor. Clin Cancer Res. 2017;23(1):171–80. https://doi.org/10.1158/1078-0432.CCR-16-0529 .
doi: 10.1158/1078-0432.CCR-16-0529
pubmed: 27370604
Lostes-Bardaji MJ, García-Illescas D, Valverde C, Serrano C. Ripretinib in gastrointestinal stromal tumor: the long-awaited step forward. Ther Adv Med Oncol. 2021;13:1758835920986498. https://doi.org/10.1177/1758835920986498 .
doi: 10.1177/1758835920986498
pubmed: 33473249
pmcid: 7797597
Garcia-Carbonero R, Carnero A, Paz-Ares L. Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 2013;14(9):e358–69. https://doi.org/10.1016/S1470-2045(13)70169-4 .
doi: 10.1016/S1470-2045(13)70169-4
pubmed: 23896275
Honma Y, Kurokawa Y, Sawaki A, Naito Y, Iwagami S, Baba H, et al. Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG). J Clin Oncol. 2021;39(15 Suppl):11524. https://doi.org/10.1200/JCO.2021.39.15_suppl.11524 .
doi: 10.1200/JCO.2021.39.15_suppl.11524
Bauer S, Yu LK, Demetri GD, Fletcher JA. Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor. Cancer Res. 2006;66(18):9153–61. https://doi.org/10.1158/0008-5472.CAN-06-0165 .
doi: 10.1158/0008-5472.CAN-06-0165
pubmed: 16982758
Shimomura A, Yamamoto N, Kondo S, Fujiwara Y, Suzuki S, Yanagitani N, et al. First-in-human phase I study of an oral HSP90 inhibitor, TAS-116, in patients with advanced solid tumors. Mol Cancer Ther. 2019;18(3):531–40. https://doi.org/10.1158/1535-7163.MCT-18-0831 .
doi: 10.1158/1535-7163.MCT-18-0831
pubmed: 30679388
Doi T, Kurokawa Y, Sawaki A, Komatsu Y, Ozaka M, Takahashi T, et al. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial. Eur J Cancer. 2019;121:29–39. https://doi.org/10.1016/j.ejca.2019.08.009 .
doi: 10.1016/j.ejca.2019.08.009
pubmed: 31536852
Wagner AJ, Severson PL, Shields AF, Patnaik A, Chugh R, Tinoco G, et al. Association of combination of conformation-specific kit inhibitors with clinical benefit in patients with refractory gastrointestinal stromal tumors: a phase 1b/2a nonrandomized clinical trial. JAMA Oncol. 2021;7(9):1343–50. https://doi.org/10.1001/jamaoncol.2021.2086 .
doi: 10.1001/jamaoncol.2021.2086
pubmed: 34236401
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04530981?recrs=abdf&cond=GIST&draw=5&rank=3 . Accessed 19 Oct 2021.
A Study of HQP1351 in Patients With GIST or Other Solid Tumors. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03594422 . Accessed 19 Oct 2021.
Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02638766?recrs=abdf&cond=GIST&draw=6&rank=13 . Accessed 19 Oct 2021.
Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib Failure. ClinicalTrials.govc. https://clinicaltrials.gov/ct2/show/NCT04193553?recrs=abdf&cond=GIST&draw=6&rank=14 . Accessed 19 Oct 2021.
A Study of Avelumab In Combination With Axitinib in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumor After Failure of Standard Therapy. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04258956?recrs=abdf&cond=GIST&draw=9&rank=42 . Accessed 19 Oct 2021.
Selinexor as a Single Agent and in Combination With Imatinib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04138381?recrs=abdf&cond=GIST&draw=10&rank=54 . Accessed 19 Oct 2021.
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04000529?recrs=abdf&cond=GIST&draw=11&rank=64 . Accessed 19 Oct 2021.
A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03475953?recrs=abdf&cond=GIST&draw=11&rank=68 . Accessed 19 Oct 2021.
Ipilimumab and Imatinib Mesylate in Advanced Cancer. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01738139 . Accessed 19 Oct 2021.
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02834013?recrs=abdf&cond=GIST&draw=12&rank=80 .
CGT9486 (formerly known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02401815 . Accessed 19 Oct 2021.
PDR001 Plus Imatinib for Metastatic or Unresectable GIST. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03609424?recrs=abdf&cond=GIST&draw=6&rank=20 . Accessed 19 Oct 2021.
Paclitaxel in Patients With GIST With Low P-glycoprotein Expression After Failure of at Least Imatinib and Sunitinib, and Regorafenib. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03944304?recrs=abdf&cond=GIST&draw=7&rank=22 . Accessed 19 Oct 2021.
Temozolomide (TMZ) In Advanced Succinate Dehydrogenase (SDH)-Mutant/Deficient Gastrointestinal Stromal Tumor (GIST). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03556384?recrs=abdf&cond=GIST&draw=7&rank=24 . Accessed 19 Oct 2021.
Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma With Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients With SDH-deficient Gastrointestinal Stromal Tumor (GIST). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04595747?recrs=abdf&cond=GIST&draw=8&rank=31 . Accessed 19 Oct 2021.
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02880020?recrs=abdf&cond=GIST&draw=8&rank=33 . Accessed 19 Oct 2021.
Treatment of Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumors in First Line With Nilotinib. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00756509?recrs=abdf&cond=GIST&draw=8&rank=37 . Accessed 19 Oct 2021.
A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04254939?recrs=abdf&cond=GIST&draw=8&rank=39 . Accessed 19 Oct 2021.
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04409223?recrs=abdf&cond=GIST&draw=9&rank=41 . Accessed 19 Oct 2021.
Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor selumetinib (AZD6244 Hydrogen Sulfate) in people with neurofibromatosis type 1 (NF1) mutated gastrointestinal stromal tumors (GIST). ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03109301 . Accessed 19 Oct 2021.
A phase II trial of the DNA methyl transferase inhibitor, guadecitabine (SGI-110), in children and adults with wild type GIST, pheochromocytoma and paraganglioma associated with succinate dehydrogenase deficiency and HLRCC-associated kidney cancer. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03165721 . Accessed 19 Oct 2021.